# US 2017/0248610 A1 · Method of predicting obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0248610 A1
- Document ID: US20170248610A1
- Status: Published application
- Kind: A1
- Application number: 15/443,266
- Filed: 2017-02-27
- Published: 2017-08-31
- Earliest claimed: 2016-02-25
- Assignees: University of Kentucky Research Foundation; University of Massachusetts; Lund University
- Applicants: University of Kentucky Research Foundation; University of Massachusetts; Lund University
- Inventors: B. Mark Evers; Jing Li; Paul Dobner; Olle Melander
- Web page: https://patentgrep.com/patent/US20170248610A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12N 2310/14: interfering nucleic acids [NA]
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2440/14: phosphorylation
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The presently disclosed subject matter relates to a method for predicting increased risk of obesity on a non-obese subject. More particularly, the presently disclosed subject matter relates to a method of predicting increased risk of obesity in a non-obese subject by determining a level of neurotensin expression in a biological sample from the subject and comparing the level of neurotensin expression in the sample with a control level. The presently disclosed subject matter further relates to a method of preventing and/or treating obesity in a subject in need thereof by administering to the subject an effective amount of an agent that inhibits neurotensin.

## Claims

### Claim 1

A method of predicting increased risk of obesity in a non-obese subject, comprising:
contacting a biological sample from the subject with a probe for neurotensin to determine the amount of neurotensin in the biological sample;
comparing the amount of neurotensin to a control level; and
determining that the subject has an increased risk of obesity if there is a measurable difference in the amount of neurotensin in the sample as compared to control level, wherein an increased neurotensin level is predictive of an increased risk of becoming obese.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
measuring the phosphorylation level of AMPK in the biological sample; and
comparing the measured phosphorylation level to a control level, wherein a decreased level of phosphorylation level is predictive for an increased risk of becoming obese.

### Claim 3 (depends on 1)

The method of claim 1, wherein the neurotensin is pro-neurotensin.

### Claim 4 (depends on 1)

The method of claim 1, wherein the risk of becoming obese is independent of baseline body mass index.

### Claim 5 (depends on 1)

The method of claim 1, wherein the biological sample comprises blood, plasma, serum, plasma, and tissue.

### Claim 6 (depends on 1)

The method of claim 1, wherein the amount of pro-neurotensin is detected by a technique comprising RNA measuring assays and protein measuring assays.

### Claim 7 (depends on 1)

The method of claim 1, wherein the RNA measuring assay comprises real time reverse transcription polymerase chain reaction.

### Claim 8 (depends on 1)

The method of claim 1, wherein the obesity is prevalent obesity.

### Claim 9 (depends on 1)

The method of claim 1, wherein the obesity is prevalent abdominal obesity.

### Claim 10 (depends on 1)

The method of claim 1, wherein the obesity is new-onset obesity.

### Claim 11 (depends on 1)

The method of claim 1, and further comprising administering to the non-obese subject preventative treatment for obesity.

### Claim 12 (depends on 11)

The method of claim 11, wherein the preventative treatment includes administration of a neurotensin inhibitor.

### Claim 13

A method of detecting reduced intestinal fat absorption in a subject, comprising:
contacting a biological sample from the subject with a probe for neurotensin to determine the amount of neurotensin in the biological sample;
comparing the amount of neurotensin to control level; and
determining that the subject has reduced intestinal fat absorption if there is a measurable difference in the amount of neurotensin in the sample as compared to control level, wherein a decreased neurotensin level is indicative of reduced intestinal fat absorption.

### Claim 14 (depends on 13)

The method of claim 13, further comprising:
measuring the phosphorylation level of AMPK in the biological sample; and
comparing the measured phosphorylation level to a control level, wherein an elevated phosphorylation level is indicative of reduced intestinal fat absorption.

### Claim 15

A method of preventing and/or treating obesity in a subject in need thereof, comprising:
administering to the subject an effective amount of an agent that inhibits neurotensin.

### Claim 16 (depends on 15)

The method of claim 15, further comprising administering a pharmaceutically acceptable carrier.

### Claim 17 (depends on 15)

The method of claim 15, wherein the agent is a neurotensin inhibitor.

### Claim 18 (depends on 15)

The method of claim 15, wherein the agent is a neurotensin receptor antagonist.

### Claim 19 (depends on 15)

The method of claim 15, wherein the agent is a small molecule or a peptide.

### Claim 20 (depends on 15)

The method of claim 15, wherein the agent is siRNA.
